RTU (Ready-To-Use) Platform
The RTU technology platform transfers the reconstitution/re-dilution needed products to a ready to use dosage forms. The platform also provides the following advantages:
-
Reduce or eliminate the use of problematic excipients, such as surfactants, etc.
-
Mainly based on aqueous solution, can reduce or not use harmful organic solvents and additives
-
RTU / RTD, and has a longer use time stability; eliminate reconstitution/ handling of cytotoxic drugs reducing contamination and medication errors
-
Can provide multiple uses/ multiple dose options
-
No novel excipients used, minimizing the possibility of requiring clinical safety and/or bioequivalence studies
-
505b2 regulatory pathway shortens development time and the product is protected by non-infringing composition patents
S4EIS (Solution for Extended-Release Injectable Suspension)
-
The technology platform is used to manufacture a new long-acting microcrystalline suspension injection drug delivery system with controllable particle size.
-
Suitable for subcutaneous or intramuscular injection (SC or IM)
-
Controlled drug release by slow release of active ingredients
-
The use of simple, conventional product production processes has obvious advantages over complex sterile suspension or sterile powder production processes
-
Suitable for the sustained release administration of a variety of high-value pharmaceutical active molecules
CPM (Continuous Process for Manufacturing Microparticle)
-
The proprietary continuous aseptic manufacturing process for microparticle manufacturing for multivesicular liposome suspension and microspheres
-
Capacity can be shared with multiple products, more efficient production process
-
Greatly reduced product manufacturing costs and speed up the market development